Precipio, inc. (PRPO)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Sep'10Jun'10
Service revenue, net

-

-

-

-

-

-

-

-

-

-

316

316

-

-

365

504

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Clinical research grants

-

-

-

-

-

-

-

-

-

-

9

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other

-

-

-

-

-

-

-

-

-

-

2

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Revenue, net of contractual allowances and adjustments

-

-

-

-

-

-

-

-

-

-

327

316

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

less allowance for doubtful accounts

-

-

-

-

-

-

-

-

-

-

57

56

-

-

80

111

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Revenue, net of contractual allowances and adjustments

1,482

933

1,046

1,199

917

870

823

959

796

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

less allowance for doubtful accounts

266

245

262

257

204

185

173

142

84

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net sales

1,216

688

784

942

713

685

650

817

712

-

270

260

-

-

445

615

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

NET SALES

-

-

-

-

-

-

-

-

-

-

-

-

658

-

-

-

236

407

330

442

750

-15,839

4,064

6,764

6,251

6,218

6,646

7,306

7,374

7,292

7,889

9,093

7,206

8,571

8,253

7,667

7,480

4,419

5,095

Service revenue

-

-

-

-

-

-

-

-

-

-

347

284

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total cost of sales

1,091

707

756

770

675

648

661

642

688

341

347

284

459

785

231

241

505

565

445

465

465

-8,300

2,347

4,371

3,757

4,142

4,196

4,333

4,119

5,626

4,089

4,531

4,102

3,288

3,808

3,112

3,326

2,402

2,608

Gross profit

125

-19

28

172

38

37

-11

175

24

194

-77

-24

199

-333

134

263

-269

-158

-115

-23

285

-7,539

1,717

2,393

2,494

2,076

2,450

2,973

3,255

1,666

3,800

4,562

3,104

5,283

4,445

4,555

4,154

2,017

2,487

OPERATING EXPENSES:
Operating expenses

-

-

2,391

2,467

-

2,085

2,831

2,358

2,178

1,550

2,541

777

1,620

-

497

-

1,704

1,657

1,686

1,908

1,804

-8,529

5,063

5,563

5,288

4,782

7,226

4,982

6,311

4,314

5,559

5,278

4,994

4,874

4,364

5,589

4,323

2,159

3,033

Impairment of goodwill

-

-

-

-

-

-

1,275

0

294

-

1,015

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Research and development

-

-

-

-

-

-

-

-

-

-

-

-

134

-

-

-

270

479

455

468

451

78

641

785

745

905

630

913

764

620

668

654

549

567

515

579

557

613

512

Impairment of long-lived assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Restructuring charges

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1

5

11

24

72

0

Operating expenses

2,328

4,258

2,391

2,467

2,097

5,201

4,106

2,358

2,472

9,716

3,556

777

1,754

4,595

497

548

1,974

2,136

2,141

2,376

2,255

-8,451

5,704

6,348

6,033

5,687

7,856

5,895

7,075

4,934

6,227

5,932

5,543

5,442

4,884

6,179

4,904

2,844

3,545

OPERATING LOSS

-2,203

-4,277

-2,363

-2,295

-2,059

-5,164

-4,117

-2,183

-2,448

-9,522

-3,633

-801

-1,555

-4,928

-363

-285

-2,243

-2,294

-2,256

-2,399

-1,970

912

-3,987

-3,955

-3,539

-3,611

-5,406

-2,922

-3,820

-3,268

-2,427

-1,370

-2,439

-159

-439

-1,624

-750

-827

-1,058

OTHER INCOME (EXPENSE):
Interest expense, net

-713

-175

-97

-178

-23

-93

-120

-48

-8

26

-1,883

-220

-247

-573

-136

-160

-169

-174

-174

-186

-190

-175

-162

-146

-182

-183

-155

-151

-153

-177

-207

-231

-273

-242

-238

-240

-238

0

1

Warrant revaluation

936

435

563

-822

240

1,158

176

323

261

-223

33

-3

-33

466

0

1

321

-175

385

-270

-145

-

-50

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss on modification of warrants

-

-

-

-1,128

-

-

-143

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Derivative revaluation

-

0

0

-438

23

-

117

-1

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Gain on settlement of liability, net

-

186

0

1,084

167

50

66

6

141

-

647

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

(Loss) gain on extinguishment of debt

-

-

-

-

-

-

284

-

-

-

-1,338

-53

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss on extinguishment of convertible notes

-1,225

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss on litigation

-

-

-

266

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss on issuance of convertible notes

-

-

-

1,870

-

-

112

928

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss on settlement of equity instruments

-

-

-

-

-

0

0

0

-385

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Merger advisory fees

-

-

-

-

-

-

-

-

-

-

73

2,603

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Warrant revaluation

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

200

50

-

0

200

-

-

-

-

-

-

-

-

-

-

-

Gain on sale of product line

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

Expense on preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-800

600

4,239

2,027

0

0

Warrant revaluation

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-400

-

0

-1,000

0

-

0

0

-

-

-

Total other nonoperating income (expense)

-

-

-

-

-

-

-

-

-

-

-2,647

-2,879

-

-

0

0

-

19

-6

0

-13

1

-1

0

0

6

1

0

53

-11

-6

8

20

29

-2

1

231

0

0

Total other expenses

-1,002

426

466

-3,618

407

-1,690

268

-648

9

-

-

-

-280

-307

-136

-159

152

-344

205

-456

-348

81

-213

54

-132

-477

-154

49

300

1,012

-213

777

-253

587

-840

-4,478

-2,034

0

1

LOSS BEFORE INCOME TAXES

-3,205

-3,851

-1,897

-5,913

-1,652

-6,854

-3,849

-2,831

-2,439

-8,899

-6,280

-3,680

-1,835

-5,235

-499

-444

-2,091

-2,638

-2,051

-2,855

-2,318

993

-4,200

-3,901

-3,671

-4,088

-5,560

-2,873

-3,520

-2,256

-2,640

-593

-2,692

428

-1,279

-6,102

-2,784

-827

-1,057

INCOME TAX BENEFIT

-

-

-

-

-

-

-

-

-

349

0

0

0

0

0

0

0

1

0

-1

0

959

-1,456

-8

505

-106

-8

-6

66

58

114

-30

4

164

-9

-104

-6

71

89

LOSS FROM CONTINUING OPERATIONS

-

-

-

-

-

-

-

-

-

-

-

-

-1,835

-

-

-

-2,091

-2,639

-2,051

-2,854

-2,318

-

-2,744

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

INCOME (LOSS) FROM DISCONTINUED OPERATIONS, NET OF TAXES

-

-

-

-

-

-

-

-

-

-

-

-

73

-

-

-

-1,173

-16,700

-5,248

-421

-723

-

2,664

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

NET LOSS

-3,205

-3,781

-1,897

-5,913

-1,652

-6,575

-3,849

-2,831

-2,439

-8,972

-6,280

-3,680

-1,762

-3,409

-499

-444

-3,264

-19,339

-7,299

-3,275

-3,041

-5,793

-80

-3,893

-4,176

-3,982

-5,552

-2,867

-3,586

-2,314

-2,754

-563

-2,696

264

-1,270

-5,998

-2,778

-898

-1,146

Deemed dividends related to beneficial conversion feature of preferred stock and fair value of warrant down round features

3,344

-

-

-

-

374

0

334

3,514

-

3,764

5,248

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Preferred dividends

-

-

-

-

-

-

-

-

-

-

84

-

0

0

0

0

393

331

331

331

331

-

304

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

TOTAL DIVIDENDS

3,344

-

-

-

-

374

0

334

3,514

-

3,848

5,248

-

-

-

-

-

-

-

-

-

-

-

305

230

183

181

181

181

165

165

165

165

208

275

267

260

0

0

NET LOSS AVAILABLE TO COMMON STOCKHOLDERS

-6,549

-3,781

-1,897

-5,913

-1,652

-6,949

-3,849

-3,165

-5,953

-12,391

-10,128

-8,928

-1,762

-3,409

-499

-444

-3,657

-19,670

-7,630

-3,606

-3,372

-6,098

-384

-4,198

-4,406

-4,165

-5,733

-3,048

-3,767

-2,479

-2,919

-728

-2,861

56

-1,545

-6,265

-3,038

-898

-1,146

BASIC AND DILUTED LOSS PER COMMON SHARE (IN DOLLARS PER SHARE)

-0.78

-0.49

-0.31

-1.05

-0.48

-1.94

-2.49

-2.29

-7.10

9.62

-1.36

-15.35

-0.07

2.01

-1.15

-1.03

-0.18

-1.57

-0.55

-0.30

-0.36

-0.79

-0.05

-0.57

-0.60

-0.57

-0.78

-0.41

-0.54

-1.45

-0.04

-0.01

-0.05

-2.40

-0.03

-0.13

-0.06

-0.02

-0.02

BASIC AND DILUTED WEIGHTED-AVERAGE SHARES OF COMMON STOCK OUTSTANDING (IN SHARES)

8,371

7,497

6,186

5,655

3,441

1,996

1,546

1,382

838

-16,235

7,430

581

26,779

69,571

435

429

20,323

13,981

13,763

12,149

9,392

7,914

7,353

7,353

7,353

7,358

7,353

7,353

7,000

-182,795

71,645

71,645

62,683

-

-

-

-

-

-

BASIC AND DILUTED WEIGHTED AVERAGE SHARES OF COMMON STOCK OUTSTANDING (IN SHARES)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

49,327

49,299

49,293

49,289

49,206

Service revenue, net [Member]
Revenue, net of contractual allowances and adjustments

1,458

926

1,020

1,195

910

837

808

899

791

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

less allowance for doubtful accounts

266

245

262

257

204

-

173

142

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net sales

1,192

681

758

938

706

-

635

757

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total cost of sales

-

-

756

770

-

623

653

585

688

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Clinical research grants [Member]
Revenue, net of contractual allowances and adjustments

-

-

-

-

-

-

13

62

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total cost of sales

-

-

-

-

-

-

8

57

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other [Member]
Revenue, net of contractual allowances and adjustments

24

7

26

4

7

8

2

-2

5

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-